Page 3 - Aurobindo Pharma

Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%

The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.

Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.

Six Indian drug firms that are doing serious business in coronavirus times

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Stocks to Watch: Aurobindo, Sun Pharma, Future Retail, Vedanta, Voda Idea

Shares of Adani Power are likely to be in focus as the company received a favourable verdict from the Supreme Court against power discoms in Rajasthan.

Aurobindo, Sun Pharma recall products in US market for defaulting norms

Leading homegrown drug makers Aurobindo Pharma and Sun Pharmaceutical Industries are recalling different products in the US market due to deviation from standard manufacturing norms.

Stocks to Watch: Tata Power, Airtel, Nykaa, ACC, NDTV, Aurobindo, Petronet

ABB, Amara Raja, Bharat Forge, Cummins, Hero MotoCorp, Hindalco, Hindustan Motors, HP Adhesives, IRB Infra, M&M, Novartis, Sun Tv, Tata Chemicals and Zomato of announce results on Thursday.

Aurobindo Pharma net profit dips 22% to Rs 604 cr in December quarter

The Hyderabad-based drug maker had reported a consolidated net profit of Rs 777.3 crore in the same period of previous fiscal

USFDA pulls up Aurobindo Pharma for manufacturing lapses at API plant

The US Food and Drug Administration (USFDA) has issued a warning letter to Aurobindo Pharma for violating current good manufacturing practice norms at its Telangana-based plant.

Aurobindo Pharma down 5% on USFDA warning letter for Hyderabad unit

The company believes that this will not impact the existing business from this facility.

Aurobindo Pharma gets warning letter from USFDA for API facility

Aurobindo Pharma on Friday said it has received a warning letter from the US health regulator for its Hyderabad-based Unit I, an API manufacturing facility.

Aurobindo Pharma arm CuraTeQ expands scope of distribution pact with Orion

Aurobindo Pharma on Tuesday said its subsidiary CuraTeQ Biologics has expanded the scope of its marketing and distribution agreement with Orion Corporation (Orion)

Sensex plunges 949pts, Nifty ends 285pts lower; Airtel, RIL, IT shares drag

The broader markets also weakened towards the end of the trade, and the BSE Midcap and Smallcap indices ended with a loss of 1.4 per cent each

Stocks to Watch: Hero MotoCorp, Aurobindo, Neogen, SPARC, telecom shares

Telecom shares may be in demand on credit of bank guarantee to the telcos

Aurobindo Pharma, Unichem Laboratories recall products in US market

Aurobindo Pharma and Unichem Laboratories are recalling different products in the US market, the world's largest market for medicines, due to manufacturing issues. As per the latest enforcement report issued by the US Food and Drug Administration (USFDA), Aurobindo's US-based unit is recalling 7,296 containers of hypertension drug Carvedilol tablets. The affected lot contains 6.25 mg Carvedilol tablets, which have been produced in India and distributed in the US by Princeton-based Aurobindo Pharma USA Inc. The company is recalling the lot due to "failed impurities/degradation specifications", the US health regulator noted in the report. Aurobindo initiated the nationwide the recall on November 15 this year, it added. Another domestic drug maker Unichem Laboratories is recalling 1,284 bottles of Topiramate tablets, used to treat epilepsy (seizures) and to prevent migraines. It is also used in the treatment of Lennox-Gastaut syndrome (a rare, but severe form of epilepsy that starts

Hero MotoCorp, Lupin, Colgate, Aurobindo, Amara Raja hit 52-week lows

In past four trading days, the S&P BSE Sensex has tanked 4 per cent or 2,412 points on concerns about European Covid-19 curbs and on risk of the US Federal Reserve speeding up stimulus withdrawal.

Strong product pipeline, valuations keep street positive on Aurobindo

The company delivered a muted show in the September quarter

Britannia, Aurobindo, Ujjivan SFB look weak on charts post Q2 results

Sobha Ltd, however, is expected to surge up to 14% indicates the daily chart.

Stocks to Watch: RIL, Aurobindo, BHEL, M&M, Jet Airways, IDFC, PowerGrid

FII fund flows, corporate earnings and ongoing IPOs likely to be in focus today

Aurobindo Pharma Q2 net profit declines nearly 14% to Rs 697 crore

The drug firm on Monday reported a decline in its consolidated net profit

Stocks to Watch: Aurobindo, Divi's, PTC, Sun Tv, Muthoot Fin, realty shares

Realty stocks on the back of PAG taking a contra call on the sector and corporate earnings will be in focus today